Zhou, Daming http://orcid.org/0000-0002-7188-5243
Supasa, Piyada
Liu, Chang
Dijokaite-Guraliuc, Aiste http://orcid.org/0000-0002-4850-9709
Duyvesteyn, Helen M. E.
Selvaraj, Muneeswaran
Mentzer, Alexander J. http://orcid.org/0000-0002-4502-2209
Das, Raksha
Dejnirattisai, Wanwisa
Temperton, Nigel http://orcid.org/0000-0002-7978-3815
Klenerman, Paul http://orcid.org/0000-0003-4307-9161
Dunachie, Susanna J. http://orcid.org/0000-0001-5665-6293
Fry, Elizabeth E. http://orcid.org/0000-0001-9754-5303
Mongkolsapaya, Juthathip http://orcid.org/0000-0003-3416-9480
Ren, Jingshan
Stuart, David I. http://orcid.org/0000-0002-3426-4210
Screaton, Gavin R. http://orcid.org/0000-0002-3549-4309
Funding for this research was provided by:
Chinese Academy of Medical Sciences (2018-I2M-2-002)
Wellcome Trust (SEACOVARIANTS, 101122/Z/13/Z)
RCUK | MRC | Medical Research Foundation (MR/N00065X/1)
Article History
Received: 22 December 2023
Accepted: 15 March 2024
First Online: 28 March 2024
Competing interests
: G.R.S. sits on the GSK Vaccines Scientific Advisory Board, consults for AstraZeneca and is a founder member of RQ Biotechnology. D.I.S. consults for AstraZeneca. Oxford University holds intellectual property related to SARS-CoV-2 mAbs discovered in G.R.S’s laboratory. S.J.D. is a Scientific Advisor to the Scottish Parliament on COVID-19. The remaining authors declare no competing interests.